Mishima, Japan

Kazuhiro Ohtsuki

This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Ono Pharmaceutical Co., Ltd.. Active years: 2010-2014.

USPTO Granted Patents = 2 


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2010-2014

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Kazuhiro Ohtsuki: Innovator in Pharmaceutical Chemistry

Introduction

Kazuhiro Ohtsuki is a notable inventor based in Mishima-gun, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that interact with S1P receptors. His work is crucial for advancing treatments for various medical conditions.

Latest Patents

Ohtsuki holds 2 patents that focus on compounds capable of binding to S1P receptors. His latest patents include a compound that is useful for the prevention and treatment of rejection of transplantation, graft-versus-host disease, autoimmune diseases, and allergic diseases. The compounds he has developed are represented by specific chemical formulas and are designed to enhance therapeutic efficacy.

Career Highlights

Kazuhiro Ohtsuki is currently employed at Ono Pharmaceutical Co., Ltd. His work at the company has positioned him as a key player in the pharmaceutical industry, contributing to innovative solutions for complex health issues. His research has the potential to impact many lives positively.

Collaborations

Ohtsuki collaborates with esteemed colleagues such as Shinji Nakade and Hirotaka Mizuno. Their combined expertise fosters a productive environment for innovation and research in pharmaceutical development.

Conclusion

Kazuhiro Ohtsuki's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…